日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

US EUROPE AFRICA ASIA 中文
Business / Companies

Xi'an Janssen plans 10 drug launches in four areas by 2020

By Wang Wen (China Daily) Updated: 2015-10-31 09:50

Xi'an Janssen Pharmaceutical Ltd, Johnson & Johnson Services Inc's largest subsidiary in China, plans to launch more than 10 new medicines in China by 2020.

Kris Sterkens, chairman of Jassen Asia Pacific, said innovation remains its core strategy, and its products will be spread over four main treatment areas: tumors, the autoimmune system, mental health and infectious and metabolic diseases such as hepatitis and diabetes.

The firm's new-product strategy, he said, was being supported by a number of recent findings that showed China has strong demand for medicine targeted at those diseases.

A survey by the Economist Intelligence Unit, a global business intelligence belonging to the Economist Group, for instance, analyzed markets in five countries across Asia Pacific including China, and reached the conclusion that "the region now carries a huge global burden of non-communicable diseases, such as cancer and mental illness".

As many as 85 percent of deaths in China in 2010 were the result of non-communicable diseases, according to the report, with cancer, cardiovascular disease and diabetes topping the list of causes.

"Healthcare systems in Asia Pacific are struggling to manage the rise in non-communicable diseases and the shift to long-term treatment of chronic conditions," said Charles Ross, the survey report's editor.

Following on from those and other findings, Xi'an Janssen will launch a new product for prostate cancer soon, said Sterkens. Research is also being conducted on a diabetes medicine.

Xi'an Janssen has launched 14 major new products in the past five years aimed at treating conditions like human immunodeficiency virus, cancer and mental illness.

Established 30 years ago, it has been a regular investor in China since its launch.

A new $290 million plant in Xi'an will be in operation from 2018, said Cesar Rodriguez, the company's chief.

The new site will have an annual capacity of 280 million medicine packages, which will be sold around the world, said Rodriguez.

Xi'an Janssen is well known in China for over-the-counter drugs such as Domperidone and Daktarin.

Johnson & Johnson combined its OTC business in China last year with Xi'an Janssen, a controversial move at the time with some industry commentators fearing the integration might hurt sales.

Rodriguez insisted the integration, named One China OTC, has achieved strong results, although he refused to detail exact numbers.

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 黄视频在线播放 | 99久久久国产 | 国产91视频在线观看 | 男人的天堂中文字幕 | 免费观看中文字幕 | 妹子色综合| 综合色婷婷一区二区亚洲欧美国产 | 久久观看最新视频 | av看看| 日韩精品视频网 | 依人99| 成人免费看片视频在线观看 | 羞羞免费视频 | 欧美日韩一区二区三区不卡 | 清清草在线视频 | 欧美交受高潮1 | 四虎国产在线 | 毛片自拍 | 久久久久久久性 | 亚洲天堂av中文字幕 | 黄色亚洲视频 | 欧美1级片| 亚洲综合天堂 | 91国内在线 | 成人p站在线观看 | 国产成人小视频在线观看 | 亚洲天堂一区在线观看 | 日韩一区二区三区在线 | 天天有av| 91免费网站在线观看 | 自拍偷拍五月天 | 四虎视频在线观看 | 色婷婷国产精品久久包臀 | 2019亚洲天堂 | 日韩美女在线视频 | 日韩在线一区二区三区 | 男人的天堂黄色 | 四虎色播 | 天天天操操操 | 欧美激情在线播放 | 国产精品久久久久久久午夜 |